Moderna, Inc. (NASDAQ:MRNA) Insider Juan Andres Sells 2,000 Shares

Moderna, Inc. (NASDAQ:MRNAGet Rating) insider Juan Andres sold 2,000 shares of Moderna stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $153.00, for a total transaction of $306,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at approximately $1,387,557. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Juan Andres also recently made the following trade(s):

  • On Wednesday, April 13th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $158.37, for a total transaction of $316,740.00.
  • On Wednesday, April 6th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $157.50, for a total transaction of $315,000.00.
  • On Wednesday, March 30th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $182.79, for a total transaction of $365,580.00.
  • On Wednesday, March 23rd, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $184.66, for a total transaction of $369,320.00.
  • On Wednesday, March 16th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $150.01, for a total transaction of $300,020.00.
  • On Thursday, February 24th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $150.00, for a total transaction of $300,000.00.
  • On Wednesday, February 16th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $150.00, for a total transaction of $300,000.00.
  • On Wednesday, February 9th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $154.26, for a total transaction of $308,520.00.
  • On Wednesday, February 2nd, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $170.89, for a total transaction of $341,780.00.

Shares of MRNA traded down $4.16 during trading hours on Friday, hitting $140.34. The stock had a trading volume of 163,585 shares, compared to its average volume of 7,960,038. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.60 and a current ratio of 1.76. The firm has a 50-day moving average price of $157.31 and a 200 day moving average price of $221.84. Moderna, Inc. has a fifty-two week low of $122.01 and a fifty-two week high of $497.49. The firm has a market capitalization of $56.56 billion, a price-to-earnings ratio of 4.98, a PEG ratio of 0.94 and a beta of 1.55.

Moderna (NASDAQ:MRNAGet Rating) last posted its earnings results on Thursday, February 24th. The company reported $11.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.83 by $1.46. Moderna had a net margin of 66.06% and a return on equity of 140.21%. The firm had revenue of $7.21 billion during the quarter, compared to analysts’ expectations of $6.73 billion. During the same period in the previous year, the business posted ($0.69) EPS. The business’s revenue was up 1163.3% compared to the same quarter last year. As a group, analysts predict that Moderna, Inc. will post 26.92 EPS for the current fiscal year.

MRNA has been the topic of several research analyst reports. Barclays dropped their target price on shares of Moderna from $404.00 to $210.00 in a research report on Friday, February 25th. SVB Leerink decreased their price objective on shares of Moderna from $81.00 to $80.00 and set an “underperform” rating for the company in a research note on Friday, March 25th. TheStreet cut shares of Moderna from a “b-” rating to a “c+” rating in a research note on Thursday, February 24th. Argus decreased their price objective on shares of Moderna from $420.00 to $350.00 in a research note on Thursday, January 6th. Finally, Morgan Stanley lifted their price objective on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $242.71.

Large investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. raised its position in Moderna by 263.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 6,698 shares of the company’s stock worth $2,578,000 after acquiring an additional 4,853 shares during the period. Stokes Family Office LLC raised its position in Moderna by 8.2% during the third quarter. Stokes Family Office LLC now owns 1,162 shares of the company’s stock worth $447,000 after acquiring an additional 88 shares during the period. Horizon Investments LLC acquired a new position in Moderna during the third quarter worth $2,137,000. Arrowstreet Capital Limited Partnership acquired a new position in Moderna during the third quarter worth $159,563,000. Finally, LPL Financial LLC raised its position in Moderna by 19.3% during the third quarter. LPL Financial LLC now owns 150,061 shares of the company’s stock worth $57,753,000 after acquiring an additional 24,239 shares during the period. Institutional investors own 60.11% of the company’s stock.

About Moderna (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

Further Reading

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.